Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients

A Multi-centre Observational Study on Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients Under Gefitinib Treatment

A multi-centre observational, non-interventional study is to dynamically monitor the changes of circulating tumor DNA (ctDNA) in late stage NSCLC patients under Gefitinib treatment.

Inclusion Criteria:

• Provision of informed consent
• Histologically confirmed stage IIIB/IV NSCLC.
• Activating EGFR mutations (G719A/C/S; Exon 19 insertion/deletion; L858R; L861Q)
• Able to comply with the required protocol and followed-up procedures, and able to receive oral medications

Exclusion Criteria:

• Histologically confirmed small cell lung cancer or other metastatic tumors
• Patient had received prior chemotherapy or EGFR-TKIs treatment
• Patients who harbor Exon20 T790M mutation